Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study
Language English Country Great Britain, England Media print-electronic
Document type Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
17550987
DOI
10.1136/jnnp.2007.120378
PII: jnnp.2007.120378
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic therapeutic use MeSH
- Atrophy MeSH
- Azathioprine therapeutic use MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Interferon beta-1a MeSH
- Interferon-beta therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnetic Resonance Imaging * MeSH
- Adolescent MeSH
- Brain pathology MeSH
- Cerebral Ventricles pathology MeSH
- Follow-Up Studies MeSH
- Neurologic Examination drug effects MeSH
- Image Processing, Computer-Assisted * MeSH
- Prednisone therapeutic use MeSH
- Disease Progression MeSH
- Multiple Sclerosis, Relapsing-Remitting diagnosis drug therapy MeSH
- Drug Administration Schedule MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Azathioprine MeSH
- Immunosuppressive Agents MeSH
- Interferon beta-1a MeSH
- Interferon-beta MeSH
- Prednisone MeSH
BACKGROUND: There is growing evidence for the concept of multiple sclerosis (MS) as an inflammatory neurodegenerative disease, with a different pattern of atrophy evolution in grey matter (GM) and white matter (WM) tissue compartments. OBJECTIVE: We aimed to investigate the evolution of different MRI measures in early relapsing-remitting patients with MS and in normal controls (NCs) over 2 years. We also evaluated the progression of these MRI measures in a subset of patients who were followed for up to 5 years. METHODS: Included in this study were 147 patients who participated in the combination ASA (Avonex Steroids Azathioprine) study and completed full treatment, clinical and MRI assessment at 0, 12 and 24 months. A subgroup of 66 patients was followed for 36 months, 51 patients for 48 months and 43 patients for 60 months. Mean age at baseline was 30.7 years, mean disease duration was 5.5 years, mean EDSS was 1.8 and mean annualised relapse rate before study entry was 1.7. MRI scans were performed on a 1.5T scanner every 2 months for the first 2 years and thereafter once yearly for up to 5 years. In addition to the MS group, 27 NCs were examined at months 0, 12 and 24 using the same MRI protocol. Percentage brain volume change (PBVC), GM volume (GMV), WM volume (WMV) and peripheral grey volume (PGV) were measured annually using SIENA/X software. T2-hyperintense lesion volume (LV), lateral ventricle volume (LVV) and third ventricle width (3VW) were also assessed annually. RESULTS: Over the period of 0-24 months, patients with MS lost significantly more GMV (-2.6% vs -0.72%, p<0.001), PGV (-2.4% vs -1.03%, p<0.001) and PBVC (-1.2% vs -0.22%, p<0.001), and increased in LVV (+16.6% vs +0.55%, p<0.003) and 3VW (+9.3% vs 0%, p = 0.003), when compared with NCs. Within-person change in MRI measures for patients with MS over 5 years was -4.2% for PBVC, -6.2% for GMV, -5.8% for PGV, -0.5% for WMV (all p<0.001), +68.7 for LVV (p<0.001), +4% for 3VW (p<0.001) and +42% for T2-LV (p<0.001). CONCLUSIONS: Our study confirmed a different pattern of GM, WM and central atrophy progression over 2 years between patients with MS and NCs. The study showed a different evolution of tissue compartment atrophy measures in patients with MS, with faster decline in cortical and deep GM regions, as well as periventricular WM regions, over a 5-year period.
References provided by Crossref.org
Time course of lesion-induced atrophy in multiple sclerosis
Establishing pathological cut-offs for lateral ventricular volume expansion rates
MRI correlates of disability progression in patients with CIS over 48 months
Clinical correlates of grey matter pathology in multiple sclerosis